During a panel session at the recent LSX World Congress industry spectators discussed the state of biopharma investing and how companies can prepare now for the return of the public markets.
Preparing For The Return Of Public Markets
Biotech investment is in abeyance after an unprecedented twelve-year run, according to Gregg Beloff, managing director of Danforth Advisors. The capital markets will be back and industry must continue to operate while the bear market persists.
More from Business Strategy
• By
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
• By
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
• By
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
• By
Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
More from In Vivo
• By
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.